• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates
Home » FDA panel splits on Abbott’s MitraClip heart implant

FDA panel splits on Abbott’s MitraClip heart implant

March 21, 2013 By Ingrid Mezo

Abbott's MitraClip heart implant

An FDA advisory panel yesterday narrowly recommended approval for the first-of-a-kind MitraClip heart implant made by Abbott (NYSE:ABT), designed to prevent blood from flowing backward across the mitral valve.

Although 8 panelists on the agency’s Circulatory System Devices Panel unanimously agreed that the MitraClip device is safe, they were evenly split on its effectiveness. Moderator Dr. Jeffrey Borer of State University of New York’s Downstate Medical Center broke the tie with his vote that available data for the device do not demonstrate reasonable assurance of effectiveness.

A majority of panelists, however, said MitraClip’s benefits outweighed its risks, with 5 panelists voting yes and 3 voting no.

Borer attributed his tie-breaker to problems interpreting data pooled from 2 different registries, neither of which were intended to be used as a pivotal data set. The registry data was used to come up with a post-hoc high-risk surgical group.

"I had a great deal of difficulty interpreting the registry data," Borer said. "At the end of the day, it was very difficult for me to know who I could say would benefit from this. I think somebody would. I think that this a potentially beneficial device, but I didn’t know who, and that was my concern, and that’s why I voted no."

"If your right shoe goes into horse poop and your left shoe goes into dog poop, it’s still poop. It’s hard to put these 2 things together and say that’s its even better than the individual," added Dr. Craig Selzman of the University of Utah’s School of Medicine.

The panel’s divided recommendations came after the federal watchdog expressed trepidation about approving the MitraClip in an executive summary released earlier this week.

"FDA believes the evidence necessary for determination of safety and effectiveness sufficient for approval of a first of a kind device should not be based on a retrospective evaluation of registry data re­ configured to support an indication for use and population for use developed post-hoc," according to the summary.

MitraClip is intended for patients who are too high-risk for open mitral valve surgery (as determined by a cardiac surgeon), but who are healthy enough otherwise to benefit from correction of mitral regurgitation.

The MitraClip device is a single sized, percutaneously implanted mechanical clip, which grasps and coats the mitral valve leaflets, resulting in "fixed approximation of the mitral leaflets throughout the cardiac cycle," according to the FDA. MitraClip, made of metal alloys and polyester fabric, consists of 3 major components: The delivery catheter, a steerable sleeve and the MitraClip device itself.

Originally manufactured by Evalve, which was acquired by Abbott Vascular in September 2009 for $410 million, the MitraClip’s original indication was much broader than the 1 the Abbott is pursuing: All patients with significant mitral valve regurgitation, rather than just those for whom surgery is too risky.

After the FDA ruled that the data from MitraClip’s original clinical trial were insufficient to support approval, Abbott Vascular narrowed the indication and performed additional post-hoc analysis.

MitraClip has been on the market in Europe for 4 years "with good results," according to Abbott Vascular.

The company is pleased with the outcome of the panel and "we look forward to continuing discussions with the agency as it further assesses the MitraClip system," Abbott Vascular chief medical officer Dr. Charles Simonton said in prepared remarks. An Abbott spokesman told MassDevice.com that the company is expecting hear back from the FDA later this year.

The agency isn’t bound by the panel’s determination but often heeds the wisdom of its advisory panels.

Inside the voting

After casting their votes, the panelists explained why they were swayed in either direction.

Walter Reed National Military Medical Center’s Dr. Michael Ferguson said he did not believe MitraClip adequately demonstrated effectiveness.

"I would really like to have this device available for people," Ferguson noted. "It’s a pretty difficult decision, but I think that they just didn’t do a good job of defining the patient population that would benefit and clearly establishing that the patients who would receive the device were not surgical candidates."

While Dr. Valluvan Jeevanandam of the University of Chicago said he believed that there could be patients who would benefit from MitraClip, he also voted no on effectiveness.

"I just hope that it’s not put into patients who would benefit from regular surgery and I think we should put as many safeguards as possible to make sure that doesn’t happen, that this is really put into a very small group of people who are truly inoperable," Jeevanandam stressed.

Despite their questions about the data, a majority of panelists voted that MitraClip’s benefits outweigh its risks.

"The data that the sponsor presented had as many holes as Swiss cheese and the FDA did a fantastic job finding every 1 of them," noted Dr. Gregory Dehmer of Scott & White Healthcare at Texas A&M University. "Nevertheless, valid scientific data is not restricted to just randomized, controlled trials. There are other data that are acceptable, and I think the totality of the data that we see today swayed me to feel like this is a device that has value for a selected group of patients.

"I think the challenge moving forward is for the agency and the sponsor to again heavily reengage themselves and find a solution that would in a limited way allow this device to be available to a select group of patients," Dehmer added.

St. Mary’s Hospital’s Dr. Marc Katz said that even though "there wasn’t a lot of risk data presented," his limited experience with 1 patient who received MitraClip and benefited from it swayed him to vote that the device’s benefits outweigh its risks.

"The patient with multiple sclerosis, a previous stroke and wheelchair-bound was probably the singular patient that I referred for this device to another institution, and she’s done remarkably well with it, so I did have that in the back of my mind," Katz explained.

"I have a hard time saying to patients, ‘OK, they’ve got to wait another 5 years to have this available," he added. "In no way do I think this was an elegant study. I think it was really poor in lot of ways. I think we’re put in a hard position here, but weighing the alternatives and putting the patients out front, that was the deciding factor."

Filed Under: Cardiac Implants, Food & Drug Administration (FDA), News Well, Replacement Heart Valves Tagged With: Abbott

In case you missed it

  • 3M Health Care Business president is leaving this year
  • Device developer SeaStar Medical hires chief medical officer
  • AccuPulse raises $10M Series A
  • Exactech announces first U.S. surgeries with its nex-gen laser cage glenoid
  • Baxter expects sales growth momentum through 2025
  • Vivera picks up new patent for electronic dose-controlled drug delivery devices
  • Stryker launches dynamic compression system for foot, ankle applications
  • Entegris opens Life Sciences Technology Center in Massachusetts
  • Glucose monitor maker Know Labs expands leadership team
  • inHeart wins FDA clearance for 3D cardiac modeling software
  • How Glytec is advancing insulin management in the hospital
  • Anumana wins FDA breakthrough nod for AI algorithm that detects pulmonary hypertension
  • FDA clears RapidAI’s pulmonary embolism triage platform
  • Report: Dexcom in talks to acquire Insulet
  • Henry Schein investors push back on executive pay
  • Alcon to pay $60M to acquire Kala Pharmaceuticals’ dry eye treatment
  • Creo Medical inks collaboration agreement with Intuitive

RSS From Medical Design & Outsourcing

  • 3M Health Care Business president is leaving this year
    3M Health Care Business Group President Mojdeh Poul will retire from the company on July 1, 2022. Poul joined Maple Grove, Minnesota-based 3M (NYSE:MMM) in 2011 as the global business VP of critical and chronic care solutions. She later became VP and general manager of the company’s food safety business and president of numerous 3M… […]
  • Iterative Scopes announces positive data in Skout AI colonoscopy algorithm clinical trial
    Iterative Scopes this week announced positive trial data in a study of its colorectal cancer screening algorithm, Skout. Cambridge, Massachusetts-based Iterative Scopes designed Skout as a computer-aided device (CADe) that uses artificial intelligence and computer vision technology to detect suspicious tissue and provide real-time feedback for gastroenterologists performing the procedure. Get the full story on… […]
  • Device developer SeaStar Medical hires chief medical officer
    SeaStar Medical has hired Dr. Kevin Chung as chief medical officer of the medtech developer starting July 1. Denver-based SeaStar is developing a platform therapy focused on hyperinflammation of vital organs. The company’s Selective Cytopheretic Device was designated as a breakthrough device by the FDA earlier this year. SeaStar is set to go public in… […]
  • Varta presents microbattery product portfolio at Computex 2022
    Varta will present its broad product portfolio of microbatteries, which make a wide range of future-proof applications possible, at Computex in Taipei starting today. Varta’s microbattery product portfolio ranges from rechargeable lithium-ion button cells to nickel metal hydride button cells, primary silver oxide cells, primary lithium button cells and cylindrical lithium batteries to hydrogen gas… […]
  • Entegris opens Life Sciences Technology Center in Massachusetts
    Entegris (Nasdaq:ENTG) announced today that it opened a new Life Sciences Technology Center in Billerica, Massachusetts. The new Life Sciences Technology Center was built to offer life sciences customers the opportunity to leverage Entegris’ cold-chain supply expertise to optimize processes, reduce costs and increase speed to market. Get the full story at our sister site,… […]
  • MedAcuity hires SVP of business development
    Medtech software development firm MedAcuity today said it has hired Simon Johnson as SVP of business development. Westford, Massachusetts-based MedAcuity said Johnson previously built the client partner team and managed strategic clients at digital consultancy Mobiquity. He also served as SVP of client services at GreenPages Technologies, responsible for driving services revenue growth leading to… […]
  • Henry Schein investors push back on executive pay
    Nearly half of Henry Schein (Nasdaq:HSIC) shareholders who voted at this month’s annual meeting voted against the company’s pay packages for top executives, according to a new SEC filing. About 48.5% of voting shareholders voted against the company’s executive pay plan in what’s known as the Say-on-Pay vote, according to vote results of the May… […]
  • Creo Medical inks collaboration agreement with Intuitive
    Creo Medical Group (LON: CREO) announced today that it has signed a multi-year collaboration agreement with Intuitive to make certain Creo surgical technologies compatible with the surgical robotic giant’s systems. The London exchange reacted by sending CREO shares up more than 4% to 100 pence apiece by the close of trading today. As of midday… […]
  • MedTrace Pharma moves forward on 15 O-water imaging tech
    MedTrace Pharma announced the first person scanned in its Rapid-Water-Flow Phase 3 clinical trial, further testing its tech to bring 15 O-water to imaging. The first subject scan took place at Aarhus University Hospital in Denmark, using 15 O-water produced, dosed and injected through MedTrace’s P3 automated delivery system. The clinical trial aims to evaluate… […]
  • Zimmer Biomet narrowly avoids shareholder rebuke on executive pay
    An unusually large share of Zimmer Biomet (NYSE:ZBH) investors voted against the orthopedics company’s pay packages for top executives at the annual shareholder meeting. About 54% of voting shareholders supported the pay packages of the company’s five top-paid executives at the May 13 meeting, according to results filed with the SEC yesterday. In 2021, nearly 93%… […]
  • BD, Mitsubishi Gas Chemical partner on better materials for plastic syringes
    BD (NYSE:BDX) announced that it partnered with Mitsubishi Gas Chemical Company on applying new technology to pre-fillable syringes. MGC develops the Oxycapt technology designed to integrate the best of plastic and glass for plastic syringes. BD and Tokyo-based MGC will work together to apply Oxycapt technology to the next generation of pre-fillable syringes (PFS) for advanced… […]

Leave a Reply

You must be logged in to post a comment.

Primary Sidebar

DeviceTalks Weekly

May 20, 2022
DeviceTalks Boston Post-Game – Editors’ Top Moments, Insulet’s Eric Benjamin on future of Omnipod 5
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World

Device Talks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our Device Talks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS